How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

640 results for

aspirin

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events. Full Text available with Trip Pro

Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events. Aspirin is the prophylactic antiplatelet drug of choice for people with cardiovascular disease. Adding a second antiplatelet drug to aspirin may produce additional benefit for people at high risk and people with established cardiovascular disease. This is an update to a previously published review from 2011.To review the benefit and harm of adding clopidogrel to aspirin therapy for preventing cardiovascular (...) trials comparing over 30 days use of aspirin plus clopidogrel with aspirin plus placebo or aspirin alone in people with coronary disease, ischaemic cerebrovascular disease, peripheral arterial disease, or at high risk of atherothrombotic disease. We excluded studies including only people with coronary drug-eluting stent (DES) or non-DES, or both.We collected data on mortality from cardiovascular causes, all-cause mortality, fatal and non-fatal myocardial infarction, fatal and non-fatal ischaemic

2017 Cochrane

2. AVURT: aspirin versus placebo for the treatment of venous leg ulcers a Phase II pilot randomised controlled trial

AVURT: aspirin versus placebo for the treatment of venous leg ulcers a Phase II pilot randomised controlled trial AVURT: aspirin versus placebo for the treatment of venous leg ulcers a Phase II pilot randomised controlled trial Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find (...) the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} This trial only recruited 27 of the target 100 participants with leg ulcers, due to many patients not meeting the eligibility criteria, and found no evidence that aspirin speeded up healing. {{author}} {{($index , , , , , , , , , , , , , , , , , , , , & . Helen Tilbrook 1 , Laura Clark 1 , Liz Cook 1 , Martin Bland 2 , Hannah Buckley 3 , Ian Chetter 4 , Jo Dumville 5 , Chris Fenner

2018 NIHR HTA programme

3. Acetylsalicylic acid (aspirin) for schizophrenia. (Abstract)

Acetylsalicylic acid (aspirin) for schizophrenia. Schizophrenia is a serious chronic mental illness affecting an estimated 21 million people worldwide and there is increasing evidence linking inflammation in the brain to the pathophysiology of schizophrenia. Antipsychotic drugs are the conventional treatment for people with schizophrenia but are not always fully effective. Acetylsalicylic acid (aspirin) is a non-steroidal anti-inflammatory drug (NSAID) with properties that inhibit (...) the proinflammatory status of the brain. Using aspirin as an adjunct (add-on) treatment to antipsychotics or as a stand-alone treatment could be a novel, relatively inexpensive option for people with schizophrenia.To review the effects of acetylsalicylic acid (aspirin) as adjunct (add-on) or as stand-alone treatment for people with schizophrenia.We searched the Cochrane Schizophrenia Group's Trials Register (last search 8 March 2018) which is based on regular searches of MEDLINE, Embase, PubMed, CINAHL, BIOSIS

2019 Cochrane

5. Aspirin (single dose) for perineal pain in the early postpartum period. Full Text available with Trip Pro

Aspirin (single dose) for perineal pain in the early postpartum period. Perineal trauma (due to spontaneous tears, surgical incision (episiotomy) or in association with operative vaginal birth) is common after vaginal birth, and is often associated with postpartum perineal pain. Birth over an intact perineum may also lead to perineal pain. There are adverse health consequences associated with perineal pain for the women and their babies in the short- and long-term, and the pain may interfere (...) with newborn care and the establishment of breastfeeding. Aspirin has been used in the management of postpartum perineal pain and its effectiveness and safety should be assessed.To determine the efficacy of a single dose of aspirin (acetylsalicylic acid), including at different doses, in the relief of acute postpartum perineal pain.We searched Cochrane Pregnancy and Childbirth's Trials Register (30 August 2016), ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP) (31 May

2017 Cochrane

6. The prognostic utility of tests of platelet function for the detection of aspirin resistance in patients with established cardiovascular or cerebrovascular disease: a systematic review and economic evaluation

The prognostic utility of tests of platelet function for the detection of aspirin resistance in patients with established cardiovascular or cerebrovascular disease: a systematic review and economic evaluation The prognostic and diagnostic utility of tests of platelet function for the detection of 'aspirin resistance' in patients with established cardiovascular or cerebrovascular disease: A systematic review and economic evaluation Journals Library An error occurred retrieving content to display (...) , please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} The prognostic utility of tests of platelet function for the detection of 'aspirin resistance' in patients with established cardiovascular or cerebrovascular disease: a systematic

2015 NIHR HTA programme

7. A new look at low-dose aspirin: Co-administration with tamoxifen in ovulation induction in anovulatory PCOS women. (Abstract)

A new look at low-dose aspirin: Co-administration with tamoxifen in ovulation induction in anovulatory PCOS women. To evaluate the efficacy of co-administration of low-dose aspirin (LDA) and tamoxifen on ovulation rates, endometrial thickness and clinical pregnancy rates in anovulatory PCOS women.A randomized clinical trial was conducted among 188 anovulatory PCOS women at Suez Canal University Hospitals, Ismailia - Egypt. Patients were divided into 2 groups. The study group received a daily

2019 Journal of gynecology obstetrics and human reproduction Controlled trial quality: uncertain

8. Oral aspirin for treating venous leg ulcers. Full Text available with Trip Pro

Oral aspirin for treating venous leg ulcers. Venous leg ulcers (VLUs) or varicose ulcers are the final stage of chronic venous insufficiency (CVI), and are the most common type of leg ulcer. The development of VLUs on ankles and lower legs can occur spontaneously or after minor trauma. The ulcers are often painful and exudative, healing is often protracted and recurrence is common. This cycle of healing and recurrence has a considerable impact on the health and quality of life of individuals (...) of compression. Non-adherence may be the principal cause of these poor results, but presence of inflammation in people with CVI may be another factor, so a treatment that suppresses inflammation (healing ulcers more quickly) and reduces the frequency of ulcer recurrence (thereby prolonging time between recurrent episodes) would be an invaluable intervention to complement compression treatments. Oral aspirin may have a significant impact on VLU clinical practice worldwide. Evidence for the effectiveness

2016 Cochrane

9. Aspirin for in vitro fertilisation. Full Text available with Trip Pro

Aspirin for in vitro fertilisation. Aspirin is used with the aim of optimising the chance of live birth in women undergoing assisted reproductive technology (ART), despite inconsistent evidence of its efficacy and safety (in terms of intraoperative bleeding during oocyte retrieval and risk of miscarriage). The most appropriate time to commence aspirin therapy and the length of treatment required are also still to be determined. This is the second update of the review first published in 2007 (...) .To evaluate the effectiveness and safety of aspirin in women undergoing ART.We searched the Cochrane Gynaecology and Fertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 4) in the Cochrane Library (searched 9 May 2016); the databases MEDLINE (1946 to 9 May 2016) and Embase (1974 to 9 May 2016); and trial registers (ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform search portal). We also examined

2016 Cochrane

10. Aspirin versus placebo in pregnancies at high risk for preterm pre-eclampsia. Full Text available with Trip Pro

Aspirin versus placebo in pregnancies at high risk for preterm pre-eclampsia. A recent multicentre placebo-controlled trial by Rolnick et al. has indicated that taking 150 mg aspirin daily in women at high risk of pre-eclampsia reduced the incidence of the disease from 4.3% to 1.5% in comparison with placebo. Although the findings of this study are important, a high proportion of women withdrew their consent and not all safety outcomes have been reported. This journal watch article discusses

2018 Obstetric medicine Controlled trial quality: uncertain

11. [EINSTEIN CHOICE: Comparison of rivaroxaban treatment and prophylactic doses with aspirin in the extended treatment of patients with venous thromboembolism]. Full Text available with Trip Pro

[EINSTEIN CHOICE: Comparison of rivaroxaban treatment and prophylactic doses with aspirin in the extended treatment of patients with venous thromboembolism]. Although many patients with venous thromboembolism (VTE) may need extended treatment, efficacy and safety issues of full- or lower-intensity anticoagulation over acetyl salicylic acid (ASA) treatment have remained to be determined. EINSTEIN CHOICE is a randomized, double-blind and phase 3 study, and compared either once-daily rivaroxaban (...) of rivaroxaban and in 1.2% of patients receiving 10 mg of rivaroxaban, in comparison to 4.4% of those receiving aspirin (hazard ratio for 20 mg of rivaroxaban vs. ASA, 0.34; 95% confidence interval [CI] 0.20 to 0.59; hazard ratio for 10 mg of rivaroxaban vs. ASA, 0.26; 95% CI 0.14 to 0.47; P<0.001 for both comparisons). Rates of major bleeding and adverse events were comparable among three treatment groups. In conclusion, in patients with VTE in equipoise for extended anticoagulation, either a treatment dose

2018 Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir Controlled trial quality: predicted high

12. Effect of low dose aspirin and dipyridamole on primary patency of arteriovenous grafts in hemodialysis patients: a randomized double-blind placebo-controlled trial Full Text available with Trip Pro

Effect of low dose aspirin and dipyridamole on primary patency of arteriovenous grafts in hemodialysis patients: a randomized double-blind placebo-controlled trial There is some evidence for the efficacy of antiplatelet therapies in increasing the vascular access patency duration or decreasing the thrombosis of arteriovenous grafts.To determine the effect of low dose aspirin and dipyridamole on primary patency of arteriovenous grafts in hemodialysis patients.This randomized, double-blind (...) , placebo-controlled trial was done at Imam Reza Hospital in Mashhad, Iran from September 10, 2015 to July 05, 2016. Sixty hemodialysis patients, after the placement of a new arteriovenous graft, were divided into three study groups which including; Group 1, who received 80 mg aspirin tablet daily, Group 2 received 80 mg aspirin plus 75 mg dipyridamole daily and Group 3 received placebo daily. Primary unassisted patency was recorded in follow-up until 12 months and the outcomes were analysed using one

2018 Electronic physician Controlled trial quality: predicted high

13. A Systematic Review on the Use of Aspirin in the Prevention of Deep Vein Thrombosis in Major Elective Lower Limb Orthopedic Surgery: An Update from the Past 3 Years. Full Text available with Trip Pro

A Systematic Review on the Use of Aspirin in the Prevention of Deep Vein Thrombosis in Major Elective Lower Limb Orthopedic Surgery: An Update from the Past 3 Years. Introduction  Currently there are no consensuses in the national guidance on thromboprophylaxis following major elective lower limb surgery. Emerging clinical evidence suggests that aspirin could be just as effective as anticoagulants with a lower cost. The aim of this study was to provide an update based on literature of the past (...) 3 years for the use of aspirin as thromboprophylaxis after knee and hip arthroplasty. Materials and Methods  MEDLINE/EMBASE search was performed with appropriate terms for original articles from 2014 to 2017. Results  Eight articles were found. Five articles concluded that aspirin was an effective prophylactic. The collation of results on the deep vein thrombosis rate involved 43,012 patients who were prescribed aspirin, of which 283 (0.66%) suffered from symptomatic deep vein thromboses

2018 Surgery journal (New York, N.Y.)

14. Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews

Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews DOI 10.3310/hta17430 Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews P Sutcliffe, M Connock, T Gurung, K Freeman, S Johnson, N-B Kandala, A Grove, B Gurung, S Morrow and A Clarke HEALTH TECHNOLOGY ASSESSMENT VOLUME 17 ISSUE 43 SEPTEMBER 2013 ISSN 1366-5278Aspirin (...) , Freeman K, Johnson S, Kandala N-B, et al. Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews. Health Technol Assess 2013;17(43). Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta Medica/EMBASE, Science Citation Index Expanded (SciSearch ® ) and Current Contents ® / Clinical Medicine.Health Technology Assessment NICE TAR and DAR ISSN 1366-5278 (Print) ISSN 2046-4924 (Online

2013 NIHR HTA programme

15. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force

Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force Guirguis-Blake JM, Evans CV, Senger CA, Rowland MG, O'Connor EA, Whitlock EP Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Guirguis-Blake JM, Evans CV, Senger CA, Rowland MG, O'Connor EA, Whitlock EP. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Synthesis No. 131. 2015 Authors' objectives

2015 Health Technology Assessment (HTA) Database.

16. Aspirin use to prevent cardiovascular disease and cancer: a decision analysis

Aspirin use to prevent cardiovascular disease and cancer: a decision analysis Aspirin use to prevent cardiovascular disease and cancer: a decision analysis Aspirin use to prevent cardiovascular disease and cancer: a decision analysis Dehmer SP, Maciosek MV, Flottemesch, TJ Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Dehmer SP (...) , Maciosek MV, Flottemesch, TJ. Aspirin use to prevent cardiovascular disease and cancer: a decision analysis. Rockville: Agency for Healthcare Research and Quality (AHRQ). AHRQ Publication No. 15-05229-EF-1. 2015 Authors' objectives To assess the net balance of benefits and harms from routine use of aspirin for primary prevention across clinically relevant age, sex, and cardiovascular disease (CVD) risk groups. Authors' conclusions Benefits are predicted to exceed harms among persons aged 40-69

2015 Health Technology Assessment (HTA) Database.

17. Aspirin use for the prevention of colorectal cancer: an updated systematic evidence review for the U.S. Preventive Services Task Force

Aspirin use for the prevention of colorectal cancer: an updated systematic evidence review for the U.S. Preventive Services Task Force Aspirin use for the prevention of colorectal cancer: an updated systematic evidence review for the U.S. Preventive Services Task Force Aspirin use for the prevention of colorectal cancer: an updated systematic evidence review for the U.S. Preventive Services Task Force Chubak J, Kamineni A, Buist DS, Anderson ML, Whitlock EP Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Chubak J, Kamineni A, Buist DS, Anderson ML, Whitlock EP. Aspirin use for the prevention of colorectal cancer: an updated systematic evidence review for the U.S. Preventive Services Task Force. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Synthesis No. 133. 2015 Authors' objectives We conducted

2015 Health Technology Assessment (HTA) Database.

18. Aspirin use in adults: cancer, all cause mortality, and harms. A systematic evidence review for the U.S. Preventive Services Task Force

Aspirin use in adults: cancer, all cause mortality, and harms. A systematic evidence review for the U.S. Preventive Services Task Force Aspirin use in adults: cancer, all cause mortality, and harms. A systematic evidence review for the U.S. Preventive Services Task Force Aspirin use in adults: cancer, all cause mortality, and harms. A systematic evidence review for the U.S. Preventive Services Task Force Whitlock EP, Williams SB, Burda BU, Feightner A, Beil T Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Whitlock EP, Williams SB, Burda BU, Feightner A, Beil T. Aspirin use in adults: cancer, all cause mortality, and harms. A systematic evidence review for the U.S. Preventive Services Task Force. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Synthesis No. 132. 2015 Authors' objectives We conducted

2015 Health Technology Assessment (HTA) Database.

19. Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. Full Text available with Trip Pro

Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. Since hypercoagulability might result in recurrent miscarriage, anticoagulant agents could potentially increase the chance of live birth in subsequent pregnancies in women with unexplained recurrent miscarriage, with or without inherited thrombophilia.To evaluate the efficacy and safety of anticoagulant agents, such as aspirin and heparin, in women with a history of at least two (...) unexplained miscarriages with or without inherited thrombophilia.We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (1 October 2013) and scanned bibliographies of all located articles for any unidentified articles.Randomised and quasi-randomised controlled trials that assessed the effect of anticoagulant treatment on live birth in women with a history of at least two unexplained miscarriages with or without inherited thrombophilia were eligible. Interventions included aspirin

2014 Cochrane

20. Aspirin as adjunctive treatment for giant cell arteritis. Full Text available with Trip Pro

Aspirin as adjunctive treatment for giant cell arteritis. Giant cell arteritis (GCA) is a common inflammatory condition that affects medium and large-sized arteries and can cause sudden, permanent blindness. At present there is no alternative to early treatment with high-dose corticosteroids as the recommended standard management. Corticosteroid-induced side effects can develop and further disease-related ischaemic complications can still occur. Alternative and adjunctive therapies are sought (...) . Aspirin has been shown to have effects on the immune-mediated inflammation in GCA, hence it may reduce damage caused in the arterial wall.To assess the safety and effectiveness of low-dose aspirin, as an adjunctive, in the treatment of giant cell arteritis (GCA).We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (2013, Issue 12), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to January 2014

2014 Cochrane

Systematic Reviews (Non-Premium)

Systematic reviews are arguably the most important way of telling if an intervention is worthwhile.  As a FREE user you have access to 100,000 less systematic reviews than a Pro user.  Upgrade today.